scholarly journals High-dose diquat poisoning: a case report

2021 ◽  
Vol 49 (6) ◽  
pp. 030006052110261
Author(s):  
Yanxia Huang ◽  
Renjing Zhang ◽  
Mei Meng ◽  
Dechang Chen ◽  
Yunxin Deng
Keyword(s):  
Renal Failure ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Multiple Organ ◽  
High Dose ◽  
Severe Respiratory Failure ◽  
Aggressive Treatment ◽  
Lung Lesions ◽  
Pulmonary Lesions ◽  
New Treatment

Diquat is a widely used herbicide that is substituted for paraquat. With paraquat off the market, cases of diquat poisoning have been gradually increasing. The kidney is the most frequently impaired organ in diquat poisoning. Few cases of multiple organ failure caused by diquat have been reported. We herein describe a 30-year-old man who orally ingested about 160 mL of enriched diquat. Despite aggressive treatment, the patient’s condition progressed to multiple organ failure and death. The pulmonary lesions in this patient were different from those previously reported. This patient did not die of renal failure but of severe respiratory failure. He exhibited three different stages of pulmonary disease. The lung lesions in this case were unique. We hope that doctors will pay more attention to the lung lesions in patients with diquat poisoning in future and find new treatment methods to save the lives of such patients.

scholarly journals Severe form of hemolytic-uremic syndrome with multiple organ failure in a child: a case report

F1000Research ◽  
2014 ◽  
Vol 3 ◽  
pp. 79
Author(s):  
Dino Mijatovic ◽  
Ana Blagaic ◽  
Zeljko Zupan
Keyword(s):  
Intensive Care Unit ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Intensive Care ◽  
Multiple Organ Failure ◽  
Hemolytic Uremic Syndrome ◽  
Organ Failure ◽  
Hemolytic Anemia ◽  
Multiple Organ ◽  
Uremic Syndrome

Introduction: Hemolytic-uremic syndrome (HUS) is a leading cause of acute renal failure in infants and young children. It is traditionally defined as a triad of acute renal failure, hemolytic anemia and thrombocytopenia that occur within a week after prodromal hemorrhagic enterocolitis. Severe cases can also be presented by acute respiratory distress syndrome (ARDS), toxic megacolon with ileus, pancreatitis, central nervous system (CNS) disorders and multiple organ failure (MOF).Case presentation: A previously healthy 4-year old Caucasian girl developed acute renal failure, thrombocytopenia and hemolytic anemia following a short episode of abdominal pain and bloody diarrhea. In the next week of, what initially appeared as typical HUS, she developed MOF, including ileus, pancreatitis, hepatitis, coma and ARDS, accompanied by hemodynamic instability and extreme leukocytosis. Nonetheless, the girl made a complete recovery after one month of the disease. She was successfully treated in the intensive care unit and significant improvement was noticed after plasmapheresis and continuous veno-venous hemodialysis.Conclusions: Early start of plasmapheresis and meticulous supportive treatment in the intensive care unit, including renal placement therapy, may be the therapy of choice in severe cases of HUS presented by MOF. Monitoring of prognostic factors is important for early performance of appropriate diagnostic and therapeutical interventions.

Impact of acute renal failure on antioxidant status in multiple organ failure

2000 ◽  
Vol 44 (3) ◽  
pp. 236-240 ◽  
Author(s):  
PH. G. H. Metnitz ◽  
M. Fischer ◽  
C. Bartens ◽  
H. Steltzer ◽  
TH. Lang ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Antioxidant Status ◽  
Multiple Organ

Continuous venovenous haemodiafiltration in acute renal failure associated with multiple organ failure: influence on outcome

1996 ◽  
Vol 7 (1) ◽  
pp. 4-10 ◽  
Author(s):  
T BOULAIN ◽  
M DELPECH ◽  
A LEGRAS ◽  
R LANOTTE ◽  
P-F DEQUIN ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Multiple Organ

scholarly journals Methylene blue for vasoplegic syndrome in cardiopulmonary bypass surgery: A systematic review and meta-analysis

2021 ◽  
pp. 021849232199852
Author(s):  
Fajar Perdhana ◽  
Nabila A Kloping ◽  
Andro P Witarto ◽  
David Nugraha ◽  
Niwanda Yogiswara ◽  
...  
Keyword(s):  
Systematic Review ◽  
Methylene Blue ◽  
Renal Failure ◽  
Mortality Rate ◽  
Multiple Organ Failure ◽  
Organ Failure ◽  
Unit Length ◽  
Multiple Organ ◽  
Morbidity Rate ◽  
Vasoplegic Syndrome

Background To evaluate the benefit of methylene blue as an adjunct treatment by assessing hemodynamic, morbidity rate, intensive care unit length of stay, and mortality rate outcomes in adult patients with vasoplegic syndrome. Methods A systematic search through electronic databases including Pubmed, Embase, Scopus, and Medline for studies assessing the use of methylene blue in patients with vasoplegic syndrome compared to control treatments. The Newcastle–Ottawa Scale tool was used for observational studies, and Jadad Scale was used for controlled trials to assess the risk of bias. Results This systematic review included six studies for qualitative synthesis and five studies for quantitative synthesis. Pooled analysis revealed that mean arterial pressure, systemic vascular resistance, heart rate, and hospital stay were not statistically significant in methylene blue administration compared to control. However, administration of methylene blue in vasoplegic syndrome patients significantly reduces renal failure (OR = 0.25; 95% CI = 0.08–0.75), development of multiple organ failure (OR = 0.09; 95% CI = 0.02–0.51), and mortality rate (OR = 0.12; 95% CI = 0.03–0.46). Conclusion Adjunct administration of methylene blue for vasoplegic syndrome patients significantly reduces renal failure, multiple organ failure, and mortality.

scholarly journals Case Report: Severe form of hemolytic-uremic syndrome with multiple organ failure in a child: a case report

F1000Research ◽  
2014 ◽  
Vol 3 ◽  
pp. 79
Author(s):  
Dino Mijatovic ◽  
Ana Blagaic ◽  
Zeljko Zupan
Keyword(s):  
Intensive Care Unit ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Intensive Care ◽  
Case Report ◽  
Multiple Organ Failure ◽  
Hemolytic Uremic Syndrome ◽  
Organ Failure ◽  
Multiple Organ ◽  
Uremic Syndrome

Introduction: Hemolytic-uremic syndrome (HUS) is a leading cause of acute renal failure in infants and young children. It is traditionally defined as a triad of acute renal failure, hemolytic anemia and thrombocytopenia that occur within a week after prodromal hemorrhagic enterocolitis. Severe cases can also be presented by acute respiratory distress syndrome (ARDS), toxic megacolon with ileus, pancreatitis, central nervous system (CNS) disorders and multiple organ failure (MOF).Case presentation: A previously healthy 4-year old Caucasian girl developed acute renal failure, thrombocytopenia and hemolytic anemia following a short episode of abdominal pain and bloody diarrhea. By the end of the first week the diagnosis of the typical HUS was established. During the second week the disease progressed into MOF that included ileus, pancreatitis, hepatitis, coma and ARDS, accompanied by hemodynamic instability and extreme leukocytosis. Nonetheless, the girl made a complete recovery after one month of the disease. She was successfully treated in the intensive care unit and significant improvement was noticed after plasmapheresis and continuous veno-venous hemodialysis.Conclusions: Early start of plasmapheresis and meticulous supportive treatment in the intensive care unit, including renal placement therapy, may be the therapy of choice in severe cases of HUS presented by MOF. Monitoring of prognostic factors is important for early performance of appropriate diagnostic and therapeutical interventions.

scholarly journals Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions

2021 ◽  
Vol 5 (5) ◽  
pp. 260-267
Author(s):  
R.R. Samigullina ◽  
◽  
V.I. Mazurov ◽  
E.A. Trofimov ◽  
◽  
...  
Keyword(s):  
Multiple Organ Failure ◽  
Organ Failure ◽  
Rheumatic Diseases ◽  
Interleukin 6 ◽  
Multiple Organ ◽  
Genetically Engineered ◽  
High Dose ◽  
Inflammatory Rheumatic Diseases ◽  
Cytokine Storm ◽  
Complex Therapy

The rapid spread of a new coronavirus infection (COVID-19) requires innovative solutions, including tactics optimization in using genetically engineered and targeted drugs in patients with immuno-inflammatory rheumatic diseases (RD). The authors studied the characteristics of the complex therapy of immuno-inflammatory RD in the COVID-19 pandemic conditions, analyzed the COVID-19 course in patients with RD who received combined therapy with genetically engineered and basic synthetic anti-rheumatic drugs and were under follow-up from March 2020 to March 2021. The researchers found that synthetic basic (methotrexate, leflunomide, etc.), targeted synthetic (tofacitinib, baricitinib, apremilast) and biologic disease-modifying antirheumatic drugs used in the RD treatment, except high-dose glucocorticoids and anti-B cell drugs (rituximab), do not have a negative effect and are not associated with a severe COVID-19 course. The use of interleukin-6 (IL-6) inhibitors is the standard pathogenetic therapy for cytokine release syndrome in COVID-19. Proactive therapy with IL-6 inhibitors provides inhibition of systemic inflammation and contributes to the suppression of cytokine storm syndrome, preventing the development of multiple organ failure and fatal outcome. KEYWORDS: rheumatic diseases, cytokine storm, multiple organ failure, genetically engineered biological drugs, interleukin-6, COVID-19. FOR CITATION: Samigullina R.R., Mazurov V.I., Trofimov E.A. Characteristics of complex therapy of immuno-inflammatory rheumatic diseases in COVID-19 pandemic conditions. Russian Medical Inquiry. 2021;5(5):260–267 (in Russ.). DOI: 10.32364/2587-6821-2021- 5-5-260-267.

Sign in / Sign up

Export Citation Format

Share Document